Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3470 Monotherapy or in Combination With Pembrolizumab in Haematologic Malignancies
NCT06137144Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of AZD3470 in Hodgkin lymphoma (HL), peripheral T-cell lymphoma (PTCL), sponsored by AstraZeneca. Started Jan 2024; status: recruiting.
02
Drugs
AZD3470
03
Conditions
Hodgkin lymphoma (HL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06137144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06137144.